Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
Chronic graft-versus-host disease (cGVHD) of the skin is a serious cause of long-term morbidity and mortality among patients who receive hematopoietic stem cell transplants. Systemic corticosteroids remain first-line treatment for cutaneous cGVHD; however, there is currently no consensus on second-line therapy for steroid-refractory disease. We herein present a case of a pediatric patient with severe cGVHD of the skin, nonresponsive to corticosteroids, who was successfully treated with a prolonged course of ruxolitinib with minimal side effects.
- Belina, ME; Driscoll, TA; Blanchard, SK; Cardones, AR
- May 2022
Volume / Issue
- 39 / 3
Start / End Page
- 432 - 433
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)
- United States